Atrial fibrillation and chads2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue 5, 2009, Pages 648-652

  Crandall, Mark A ^a   Horne, Benjamin D ^b,c   Day, John D ^b   Anderson, Jeffrey L ^b,c   Muhlestein, Joseph B ^b,c   Crandall, Brian G ^b   Weiss, J Peter ^b   LappÉ, Donald L ^b   Bunch, T Jared ^b  

^a MAYO CLINIC   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Atrium; Fibrillation; Inflammation; Risk factors

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOOD ANALYSIS; CLINICAL EVALUATION; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; STROKE;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; INCIDENCE; MALE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTAH;

EID: 65649087104     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02339.x     Document Type: Article

References (42)

1. Page RL. Clinical practice. Newly diagnosed atrial fibrillation. N Engl J Med 2004 351 : 2408 2416.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002 113 : 359 364. (Pubitemid 35223606)
3. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J Am Coll Cardiol 2007 50 : 2021 2028. (Pubitemid 350087568)
4. Anderson JL, Allen Maycock CA, Lappe DL, Crandall BG, Horne BD, Bair TL, Morris SR, et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 2004 94 : 1255 1259. (Pubitemid 39469943)
5. Taylor GS, Muhlestein JB, Wagner GS, Bair TL, Li P, Anderson JL. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 1998 136 : 792 803. (Pubitemid 28506878)
6. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001 285 : 2864 2870. (Pubitemid 32537350)
7. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003 163 : 936 943. (Pubitemid 36519739)
8. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006 47 : 1997 2004.
9. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998 32 : 695 703. (Pubitemid 28435256)
10. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation 2004 109 : 2839 2843. (Pubitemid 38780296)
11. Aidietis A, Laucevicius A, Marinskis G. Hypertension and cardiac arrhythmias. Curr Pharm Des 2007 13 : 2545 2555. (Pubitemid 47423668)
12. Hennersdorf MG, Schueller PO, Steiner S, Strauer BE. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. Hypertens Res 2007 30 : 535 540. (Pubitemid 47086217)
13. Kitzman DW, Edwards WD. Age-related changes in the anatomy of the normal human heart. J Gerontol 1990 45 : M33 M39. (Pubitemid 20104829)
14. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008 51 : 1 11.
15. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 2008 101 : 634 638.
16. Peterson LR, Waggoner AD, de las Fuentes L, Schechtman KB, McGill JB, Gropler RJ, Dávila-Román VG. Alterations in left ventricular structure and function in type-1 diabetics: A focus on left atrial contribution to function. J Am Soc Echocardiogr 2006 19 : 749 755. (Pubitemid 43817468)
17. Liu T, Li G. Inflammation: Another potential mechanism between diabetes mellitus and atrial fibrillation. Am J Cardiol 2008 101 : 1681 1682.
18. Lip GY, Varughese GI. Diabetes mellitus and atrial fibrillation: Perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005 105 : 319 321. (Pubitemid 41613592)
19. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Young MS, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004 147 : 931 938. (Pubitemid 38881011)
20. Bautista LE, Atwood JE, O'Malley PG, Taylor AJ. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis 2004 15 : 331 336. (Pubitemid 39299248)
21. Nelson SM, Sattar N, Freeman DJ, Walker JD, Lindsay RS. Inflammation and endothelial activation is evident at birth in offspring of mothers with type 1 diabetes. Diabetes 2007 56 : 2697 2704. (Pubitemid 350044911)
22. Asselbergs FW, Van Den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol 2005 98 : 73 77. (Pubitemid 40169856)
23. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003 108 : 3006 3010. (Pubitemid 37553570)
24. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001 104 : 2886 2891. (Pubitemid 33139098)
25. Dernellis J, Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol 2006 97 : 245 248. (Pubitemid 43139244)
26. Roldan V, Marin F, Blann AD, García A, Marco P, Sogorb F, Lip GY. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003 24 : 1373 1380. (Pubitemid 36917709)
27. Crandall MA, Corson MA. Use of biomarkers to develop treatment strategies for atherosclerosis. Curr Treat Options Cardiovasc Med 2008 10 : 304 315.
28. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004 148 : 462 466. (Pubitemid 39265119)
29. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006 108 : 346 353. (Pubitemid 43339801)
30. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 2008 51 : 1790 1793.
31. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, Oliver C, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006 97 : 55 60. (Pubitemid 41828123)
32. Ozaydin M, Dogan A, Varol E, Kapan S, Tuzun N, Peker O, Aslan SM, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007 107 : 117 121. (Pubitemid 46272262)
33. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006 97 : 1490 1493.
34. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003 92 : 1343 1345.
35. Al Chekakie MO, Akar JG, Wang F, Al Muradi H, Wu J, Santucci P, Varma N, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007 18 : 942 946. (Pubitemid 47339045)
36. Richter B, Derntl M, Marx M, Lercher P, Gossinger HD. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: No effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007 153 : 113 119.
37. Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, Hippeläinen M, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA 2007 297 : 1562 1567. (Pubitemid 46588369)
38. Yared JP, Bakri MH, Erzurum SC, Moravec CS, Laskowski DM, Van Wagoner DR, Mascha E, et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: Prospective, randomized, double-blind, placebo-controlled trial. J Cardiothorac Vasc Anesth 2007 21 : 68 75. (Pubitemid 46199221)
39. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004 25 : 1100 1107. (Pubitemid 38842447)
40. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: A randomized, controlled trial. J Am Coll Cardiol 2005 45 : 1723 1728. (Pubitemid 40704512)
41. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: A review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol 2007 18 : 1222 1228. (Pubitemid 47610624)
42. Brouwer IA, Geelen A, Katan MB. n-3 Fatty acids, cardiac arrhythmia and fatal coronary heart disease. Prog Lipid Res 2006 45 : 357 367. (Pubitemid 43818132)